TCBP logo

TC Biopharm (Holdings) (TCBP) Financials

Balance sheets

01 Mar 202401 June 202301 Mar 202331 Dec 202230 June 202231 Dec 202130 Sept 202131 Dec 2020

Total Assets

$9.2 M(-11.7%)$10.4 M-$13.7 M(-17.0%)$16.5 M(+52.0%)$10.8 M(+13.0%)$9.6 M(-3.2%)$9.9 M

Current Assets

$5.3 M(-15.0%)$6.2 M-$9.0 M(-24.3%)$11.9 M(+128.9%)$5.2 M(+39.8%)$3.7 M(+23.2%)$3.0 M

Non Current Assets

$3.9 M(-6.6%)$4.1 M-$4.7 M(+2.2%)$4.6 M(-19.1%)$5.6 M(-4.0%)$5.9 M(-14.8%)$6.9 M

Total Liabilities

$7.8 M(-0.5%)$7.8 M-$13.3 M(-12.9%)$15.2 M(-54.1%)$33.2 M(+24.8%)$26.6 M(+83.8%)$14.5 M

Current Liabilities

$6.0 M(+4.6%)$5.8 M-$11.1 M(+4.8%)$10.6 M(-61.9%)$27.8 M(+36.3%)$20.4 M(+257.1%)$5.7 M

Long Term Liabilities

$1.8 M(-14.5%)$2.1 M-$2.2 M(-53.2%)$4.6 M(-14.0%)$5.4 M(-12.9%)$6.2 M(-29.1%)$8.8 M

Shareholders Equity

$1.4 M(-46.1%)$2.5 M-$400.9 K(-67.6%)$1.2 M(+105.5%)-$22.3 M(-31.5%)-$17.0 M(-272.6%)-$4.6 M

Book Value

$1.4 M(-46.1%)$2.5 M-$400.9 K(-67.6%)$1.2 M(+105.5%)-$22.3 M(-31.5%)-$17.0 M(-272.6%)-$4.6 M

Working Capital

-$708.0 K(-243.9%)$492.0 K--$2.1 M(-256.2%)$1.3 M(+105.9%)-$22.6 M(-35.5%)-$16.7 M(-520.4%)-$2.7 M

Cash And Cash Equivalents

$1.2 M(-48.8%)$2.4 M-$5.8 M(-20.0%)$7.3 M(+244.0%)$2.1 M(+1.6%)$2.1 M(+104.3%)$1.0 M

Accounts Payable

$2.4 M(+102.3%)$1.2 M-$1.1 M(-47.9%)$2.0 M(+6.7%)$1.9 M(+4.2%)$1.8 M(+111.8%)$870.0 K

Accounts Receivable

--------

Short Term Debt

$389.0 K(-53.6%)$837.8 K-$1.2 M(-32.3%)$1.8 M(-82.8%)$10.2 M(+41.8%)$7.2 M(+1094.9%)$603.3 K

Long Term Debt

$1.8 M(-14.5%)$2.1 M-$2.2 M(-8.7%)$2.4 M(-17.4%)$2.9 M(-5.0%)$3.0 M(-13.7%)$3.5 M

Total Debt

$2.2 M(-25.7%)$2.9 M(+100.0%)$0.0(-100.0%)$3.4 M(-18.7%)$4.1 M(-68.4%)$13.1 M(+27.9%)$10.2 M(+148.5%)$4.1 M

Debt To Equity

1.6(+37.9%)1.2-8.4(+150.4%)3.4(+917.1%)-0.4(-5.1%)-0.4(-100.0%)0.0

Current Ratio

0.9(-19.3%)1.1-0.8(-28.3%)1.1(+494.7%)0.2(+5.6%)0.2(-66.0%)0.5

Quick Ratio

--------

Inventory

--------

Retained Earnings

-$53.2 M(-27.0%)-$41.9 M--$40.4 M(-3.7%)-$39.0 M(+13.8%)-$45.2 M(-13.8%)-$39.7 M(-46.5%)-$27.1 M

PB Ratio

2.4(-70.5%)8.0-167.1(+40.3%)119.1---

Income statements

01 Mar 202401 June 202301 Mar 202331 Dec 202230 June 202231 Dec 202130 Sept 202131 Dec 2020

EPS

-$27.9(-174.4%)$37.5(+149.8%)-$75.4---$2689.3(+45.7%)-$4956.3(-697.9%)-$621.1

TTM EPS

$9.6(+125.4%)-$37.8(+49.8%)-$75.4---$7645.5(-37.1%)-$5577.4(-797.9%)-$621.1

Revenue

-----$666.8 K(-2.2%)$682.0 K(+4.5%)$652.7 K

TTM Revenue

-----$1.3 M(+1.1%)$1.3 M(+104.5%)$652.7 K

Total Expenses

$4.4 M(-0.9%)$4.4 M(-13.0%)$5.1 M--$3.8 M(+4.1%)$3.7 M(+31.3%)$2.8 M

Operating Expenses

$4.4 M(-0.9%)$4.4 M(-13.0%)$5.1 M--$3.8 M(+4.1%)$3.7 M(+31.3%)$2.8 M

Cost Of Goods Sold

--------

TTM Cost Of Goods Sold

--------

Gross Profit

--------

TTM Gross Profit

--------

Gross Margin

--------

Operating Profit

-$4.4 M(+0.9%)-$4.4 M(+13.0%)-$5.1 M---$3.1 M(-5.5%)-$3.0 M(-39.5%)-$2.1 M

TTM Operating Profit

-$8.8 M(+7.4%)-$9.5 M(-87.0%)-$5.1 M---$6.1 M(-19.7%)-$5.1 M(-139.5%)-$2.1 M

Operating Margin

------470.4%(-7.9%)-435.8%(-33.5%)-326.4%

Net Income

-$4.2 M(-440.5%)$1.2 M(+260.3%)-$771.7 K---$5.3 M(+45.7%)-$9.7 M(-456.0%)-$1.7 M

TTM Net Income

-$3.0 M(-739.2%)$465.6 K(+160.3%)-$771.7 K---$14.9 M(-30.7%)-$11.4 M(-556.0%)-$1.7 M

Net Margin

------788.4%(+44.5%)-1420.7%(-432.1%)-267.0%

EBIT

-$4.4 M(-188.0%)$5.0 M(+198.0%)-$5.1 M---$3.5 M(+58.7%)-$8.5 M(-298.1%)-$2.1 M

TTM EBIT

$594.6 K(+674.5%)-$103.5 K(+98.0%)-$5.1 M---$12.0 M(-12.9%)-$10.6 M(-398.1%)-$2.1 M

EBITDA

-$4.2 M(-179.6%)$5.3 M(+209.1%)-$4.8 M---$3.2 M(+61.1%)-$8.1 M(-358.1%)-$1.8 M

TTM EBITDA

$1.1 M(+145.1%)$440.4 K(+109.1%)-$4.8 M---$11.3 M(-14.0%)-$9.9 M(-458.1%)-$1.8 M

Selling, General & Administrative Expenses

$2.7 M(+57.8%)$1.7 M(-36.5%)$2.7 M--$1.6 M(+9.8%)$1.4 M(+97.0%)$733.0 K

TTM SG&A

$4.4 M(+0.1%)$4.4 M(+63.5%)$2.7 M--$3.0 M(+39.2%)$2.2 M(+197.0%)$733.0 K

Depreciation And Amortization

$161.1 K(-51.3%)$330.5 K(+50.2%)$220.0 K---$1.1 M-

TTM D&A

$491.6 K(-10.7%)$550.5 K(+150.2%)$220.0 K---$1.1 M-

Interest Expense

-----$2.6 M(+62.9%)$1.6 M(+1642.3%)$91.3 K

TTM Interest Expense

-----$4.2 M(+148.6%)$1.7 M(+1742.3%)$91.3 K

Income Tax

-$140.5 K(+62.6%)-$375.5 K(+22.8%)-$486.2 K---$835.9 K(-120.5%)-$379.1 K(+20.7%)-$478.3 K

TTM Income Tax

-$516.0 K(+40.1%)-$861.7 K(-77.2%)-$486.2 K---$1.2 M(-41.7%)-$857.4 K(-79.3%)-$478.3 K

PE Ratio

1.4-------

PS Ratio

--------

Cashflow statements

01 Mar 202401 June 202301 Mar 202331 Dec 202230 June 202231 Dec 202130 Sept 202131 Dec 2020

Cash From Operations

-$3.1 M(+34.5%)-$4.7 M(-31.7%)-$3.5 M----$4.2 M-

TTM CFO

-$7.7 M(+5.9%)-$8.2 M(-131.7%)-$3.5 M----$4.2 M-

Cash From Investing

-$7100.0(+92.5%)-$94.9 K(+46.2%)-$176.5 K----$125.7 K-

TTM CFI

-$102.0 K(+62.4%)-$271.4 K(-53.8%)-$176.5 K----$125.7 K-

Cash From Financing

$1.2 M(+497.7%)$197.9 K(-95.9%)$4.8 M---$5.4 M-

TTM CFF

$1.4 M(-72.4%)$5.0 M(+4.1%)$4.8 M---$5.4 M-

Free Cash Flow

-$3.1 M(+35.6%)-$4.8 M(-28.0%)-$3.7 M----$4.3 M-

TTM FCF

-$7.8 M(+7.7%)-$8.5 M(-128.0%)-$3.7 M----$4.3 M-

CAPEX

------$125.7 K-

TTM CAPEX

------$125.7 K-

Dividends Paid

--------

TTM Dividends Paid

--------

TTM Dividend Per Share

--------

TTM Dividend Yield

--------

Payout Ratio

--------